ANDA bulk supplier change for cGMP problems will not require in vivo study in most cases -- FDA.
Executive Summary
ANDA BULK SUPPLIER CHANGE FOR cGMP REASONS WILL NOT REQUIRE NEW IN VIVO STUDY to demonstrate bioequivalence with the previous supplier under a new policy established by FDA's Office of Generic Drugs. "Effective immediately, for unapproved applications OGD will allow substitution of an alternate source of the [new drug substance] based on assurance that the specifications and test data are essentially the same as those of the original source used in the exhibit batch (and bioequivalence study, if required) that would have been acceptable except for CGMP issues," a July 26 OGD memo states.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth